
Sign up to save your podcasts
Or
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
4.8
179179 ratings
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
322 Listeners
111 Listeners
505 Listeners
694 Listeners
60 Listeners
280 Listeners
3,336 Listeners
1,116 Listeners
194 Listeners
45 Listeners
517 Listeners
362 Listeners
254 Listeners
60 Listeners
40 Listeners